/
RSS Feed
Bengt Eriksson
REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
I am a medicine student in Turkey and I am hoping to have my specialty in Orthotics. I am really glad to listen such a nice podcast about current progresses in the field, I hope I can make similar research in the field as well.